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Background: T1 mapping is a robust and highly reproducible application to quantify myocardial relaxation of
longitudinal magnetisation. Available T1 mapping methods are presently site and vendor specific, with variable
accuracy and precision of T1 values between the systems and sequences. We assessed the transferability of a T1
mapping method and determined the reference values of healthy human myocardium in a multicenter setting.
Methods: Healthy subjects (n = 102; mean age 41 years (range 17–83), male, n = 53 (52%)), with no previous
medical history, and normotensive low risk subjects (n=113) referred for clinical cardiovascular magnetic resonance
(CMR) were examined. Further inclusion criteria for all were absence of regular medication and subsequently
normal findings of routine CMR. All subjects underwent T1 mapping using a uniform imaging set-up (modified
Look- Locker inversion recovery, MOLLI, using scheme 3(3)3(3)5)) on 1.5 Tesla (T) and 3 T Philips scanners. Native
T1-maps were acquired in a single midventricular short axis slice and repeated 20 minutes following gadobutrol.
Reference values were obtained for native T1 and gadolinium-based partition coefficients, λ and extracellular
volume fraction (ECV) in a core lab using standardized postprocessing.
Results: In healthy controls, mean native T1 values were 950 ± 21 msec at 1.5 T and 1052 ± 23 at 3 T. λ and ECV
values were 0.44 ± 0.06 and 0.25 ± 0.04 at 1.5 T, and 0.44 ± 0.07 and 0.26 ± 0.04 at 3 T, respectively. There were no
significant differences between healthy controls and low risk subjects in routine CMR parameters and T1 values. The
entire cohort showed no correlation between age, gender and native T1. Cross-center comparisons of mean values
showed no significant difference for any of the T1 indices at any field strength. There were considerable regional
differences in segmental T1 values. λ and ECV were found to be dose dependent. There was excellent inter- and
intraobserver reproducibility for measurement of native septal T1.
Conclusion: We show transferability for a unifying T1 mapping methodology in a multicenter setting. We provide
reference ranges for T1 values in healthy human myocardium, which can be applied across participating sites.
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The increasing contribution of cardiovascular magnetic
resonance (CMR) in clinical management is due to its
accurate measurements and versatility of the imaging
readouts, providing a comprehensive assessment of car-
diac function and structure. Insights provided by tissue
characterization using late gadolinium enhancement
(LGE) imaging, inform on the underlying etiology, relate
to prognosis and guide treatment [1-5]. LGE relies on
visual and semi-quantitative determination of relative
myocardial differences commonly presenting with char-
acteristic patterns of LGE distribution [6]. As it requires
regional relative differences between normal and abnor-
mal tissue, it is limited in revealing diffuse myocardial
disease, where abnormal and normal tissue are intertwined
[7]. Recent advances in image acquisition and quantitative
postprocessing now allow fast tissue characterisation based
on the absolute quantifiable differences in recovery rates of
longitudinal magnetisation by T1 mapping [8]. T1 mapping
is emerging as a robust and highly reproducible application
to provide meaningful measures reflecting biologically
important myocardial properties [9]. Currently proposed
T1-based indices and potential novel measures include
native T1, which reflects myocardial disease involving the
myocyte and interstitium without the need for gadolinium
based contrast agents (GBCA); and extracellular volume
fraction (ECV), a direct GBCA-based measurement of the
size of the extracellular space, reflecting only intersti-
tial disease. Emerging evidence shows that myocardial
T1-values correlate with the content of underlying
myocardial fibrosis, they are abnormal in a variety of heart
conditions and also reflect pathological substrates such as
oedema or infiltration [9].
Despite a recognized potential for clinical application,
there is an identified lack of standardization and trans-
ferability of T1 mapping methods beyond a single and
commonly expert center. Setups of available T1 mapping
methods are presently site and vendor specific, with
variable accuracy and precision of T1 values between
the systems and sequences [10]. Considerable differences
in image acquisition, post-processing approaches and pro-
posed clinical applications further complicate the use of T1
values as standard application in clinical decision-making
[11,12]. Finally, because T1 mapping is presently used in
a research (or work-in- progress, WIP) domain and not
yet a clinical product for all vendors, the experience is
concentrated to a few specialist centers. We established
a multicenter consortium of CMR centers that adopted
a uniform T1 mapping methodology, which is supported
by a single vendor platform. We assessed the transferability
of a T1 mapping method in terms of the standardized
acquisition and postprocessing approach, and determined
biological reference values of human myocardium in a
multicenter setting.Methods
Multicenter consortium
Standardized T1-mapping sequence and imaging protocol,
developed and validated at King’s College London (KCL)
[13-16], were distributed to 4 CMR centers using 1.5
and 3 T Philips scanners (University of Leeds (UL),
United Kingdom; German Heart Institute Berlin (DHZB),
Germany and St Vincent University (StVU), Sydney,
Australia). The participating centers were identified via
the worldwide Philips Healthcare clinical science net-
work and hold individual partnership research agreements,
allowing for adequate clinical science support and provision
of compatible sequences and scanner software packages.
Imaging parameters were unified across participating sites.
Concordance of local T1-values with KCL values was
established in preliminary experiments using standardized
phantoms (Eurospin II Test System®) at each location for
each field strength, as well as healthy subjects scanned at
each location. The respective local ethical review panels
approved the study protocols and all subjects provided
written informed consent.
Study population
Healthy subjects with no significant medical history, no
evidence of cardiovascular disease (normal ECG, normal
cardiac dimensions and function by cine CMR, normal
tissue characterization) or taking any regular medication,
were included (n = 102). An independent group of normo-
tensive subjects referred for clinical CMR with a low pretest
probability of cardiomyopathy or cardiac disease, taking
no medication, and with subsequently normal findings
on routine CMR, were used as a comparative cohort
(n = 113) [17]. Characteristics were recorded for all
subjects, including age, gender, body mass index, heart
rate and blood pressure. Exclusion criteria were the
generally accepted contraindications to CMR (implantable
devices, cerebral aneurysm clips, cochlear implants, se-
vere claustrophobia) or a history of renal disease with a
current eGFR < 60 mL/min/1.73 m2.
CMR protocol
CMR studies were performed with the patient supine
using clinical 1.5 T or 3 T scanners (Achieva or Ingenia,
Philips Healthcare, Best, The Netherlands) equipped with
advanced cardiac package, radiofrequency magnetic field
shimming (MultiTransmit) technology and a 32-channel
coil. Subjects underwent a standardized imaging protocol
for assessment of cardiac function and size, as described
previously [14-16]. Contrast-enhanced study was performed
in a total of 179 subjects (healthy volunteers, n = 66, 65%;
low risk subjects, n = 113, 100%). Balanced steady state free
precession, single breath-hold modified inversion recovery
Look-Locker (MOLLI) was used for T1 mapping and per-
formed in a single mid-ventricular short axis slice, prior to
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ively (TE/TR/flip-angle (FA): 1.64 ns/3.3 ns/50°, voxel
size 1.8 × 1.8 × 8 mm, phase encoding steps n = 166, 11
images from three inversions (3 + 3 + 5) with three-
heartbeat pauses prior to the second and third inver-
sions and an adiabatic prepulse) [13-16]. Intravenous
gadobutrol (Bayer Healthcare, Leverkusen, Germany)
was administered in doses 0.1, 0.15 or 0.2 mmol/kg per
body weight, as per the local clinical protocol.
Image analysis
All routine CMR analysis was performed using commercially
available software (ViewForum, Extended Workspace,
Philips Healthcare, The Netherlands), as previously de-
scribed [14-16].
Myocardial T1 relaxation was measured by placing a
region of interest (ROI) conservatively within the septal
myocardium, as previously described [13-16] (Figure 1). T1
values were also measured for the complete mid-ventricular
SAX slice as well as for 6 equiangular segments (7–12) [18].
Care was taken to avoid contamination with signal from
the blood pool. Following offline image co-registration and
motion correction, T1 values were determined by fitting an
exponential model to the measured data applying Look-
Locker, noise and heart rate correction, as previously
described [13-16]. In addition to the T1 measurements
of native myocardium and blood pool, we calculated the
myocardial partition coefficient (λ) and extracellular
volume fraction (ECV) according to the formulas [19]:
a. λ = ΔR1myocardium/ΔR1blood where R1 = 1/T1
measured before and twenty minutes after GBCA
administration.
b. ECV = λ(1 − hematocrit).
Statistical analysis
Statistical analysis was performed using SPSS software
(SPSS Inc., Chicago, IL, USA, version 20.0). Normality ofFigure 1 Illustration of T1 measurements by ROI placements in septa
myocardium in short axis slice (SAX) (C).distributions was tested with the Kolmogorov-Smirnov
statistic. Categorical data are expressed as percentages, and
continuous variables as mean ± SD or median (interquartile
range), as appropriate. For comparison of two and more
than two normally distributed variables, Student’s t-test and
one-way analysis of variance (ANOVA, with Bonferroni’s
post-hoc test) as appropriate. Associations were explored
by single and multivariate linear regressions. Images
considered of sufficient quality and free of artefacts
[20] to be deemed diagnostic were used for analysis of
septal native T1. Inter- and intraobserver reproducibility
and agreement of post-processing approaches was assessed
according to the method of Bland and Altman. Because
hematocrit has been only available in 34% of all subjects,
missing values for calculation of ECV were obtained using
multiple imputation method [21]. All values are reported as
mean ± SD and a p-value of less than 0.05 was considered
statistically significant.
Results
Contribution of cases per recruiting centers was as follows:
KCL (n = 146, 68%; 1.5 T: n = 101, 3 T, n = 45), DHZB
(n = 46, 22%, all 3 T), UL (n = 14, 7%, all 3 T), StVU
(n = 9, 4%, all 1.5 T). Subject characteristics for healthy
volunteers and low risk patients are presented in Table 1.
There were no differences in mean age or gender represen-
tation and routine CMR measures between field strengths
(p > 0.05), as well as between the two groups (Figure 2).
Comparison of T1 values per field strength
In healthy controls, mean native T1 values were 950 ±
21 msec at 1.5 T and 1052 ± 23 at 3 T, whereas λ and
ECV values were 0.44 ± 0.06 and 0.25 ± 0.04 at 1.5 T,
and 0.44 ± 0.07 and 0.26 ± 0.04 at 3 T, respectively
(Table 1). There were no significant differences between
healthy controls and low risk subjects in routine CMR
parameters and T1 values (Figure 2). Mean native T1
was significantly higher at 3 T compared to 1.5 T forl myocardium (A), blood pool (B), and by coverage of






(n = 102) (n = 113) (p-value)
Age (years) 41 ± 17 44 ± 14 0.21
Gender (male(n,%)) 53 (52) 57 (51) 0.88
BMI 26 ± 4 26 ± 4 0.97
Heart rate (bpm) 66 ± 11 67 ± 13 0.26
Systolic BP (mmHg) 119 ± 11 121 ± 15 0.27
Diastolic BP (mmHg) 71 ± 11 75 ± 9 0.39
eGFR (ml/m2) 92 ± 36 97 ± 25 0.57
Hematocrit (%) 40 ± 0.04 41 ± 0.04 0.91
LV-EDV index (ml/m2) 79 ± 15 77 ± 13 0.41
LV-ESV index (ml/m2) 30 ± 8 30 ± 7 0.79
LV-EF (%) 63 ± 5 62 ± 5 0.37
RV-EF (%) 59 ± 7 58 ± 7 0.89
LV mass index (g/m2) 51 ± 12 53 ± 13 0.21
LA area (g/m2) 22 ± 4 21 ± 4 0.49
1.5 T (n = 34) (n = 58)
Native T1myocardium (msec) 950 ± 21 952 ± 23 0.66
Native T1blood (msec) 1551 ± 115 1572 ± 111 0.36
Postcontrast T1 myocardium (msec) 415 ± 113 406 ± 94 0.77
Postcontrast T1 blood (msec) 291 ± 122 278 ± 107 0.51
λ 0.44 ± 0.06 0.43 ± 0.08 0.72
ECV 0.25 ± 0.04 0.26 ± 0.06 0.32
3 T (n = 32) (n = 55)
Native T1myocardium (msec) 1052 ± 23 1053 ± 24 0.51
Native T1blood (msec) 1736 ± 139 1716 ± 149 0.64
Postcontrast T1 myocardium (msec) 421 ± 131 402 ± 117 0.81
Postcontrast T1 blood (msec) 277 ± 106 250 ± 112 0.69
λ 0.44 ± 0.07 0.43 ± 0.09 0.46
ECV 0.26 ± 0.04 0.26 ± 0.06 0.72
BMI – Body mass index, BP – blood pressure. Student t-test, P < 0.05 is
considered significant. A total of 179 subjects underwent a contrast-enhanced
study (healthy volunteers, n = 66; patients, n = 113). Student t-test or one-way
ANOVA, P < 0.05 is considered significant.
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two partition coefficient variables: 1.5 T: r = 0.92, 3 T:
r = 0.94, (p < 0.001 for both).
Comparison of T1 values for post-processing approaches
Age-gender matched samples of subjects from each site
(n = 7 per site, a total of 28) were examined for segmental
values and average T1 value per short-axis (SAX) slice
(Figure 3). As expected, there were considerable regional
differences in T1 values in controls with the highest
values in inferior septal segments (segment 9, native
T1 (msec) – 1.5 T: 995 ± 23; 3 T: 1107 ± 21) and the lowest
values in anterolateral segments (segment 12, native T1(msec) – 1.5 T 902 ± 59; 3 T: 1029 ± 67) at both field
strengths (native T1, one-way ANOVA for 6 segments
comparisons: 1.5 T: F = 8.0, p < 0.01; 3 T F = 3.1, p < 0.05).
Compared to septal native T1 (msec, 1.5 T: 3 T:), native
T1 values averaged per SAX slice were significantly
lower (native T1 (msec) septal vs. SAX: 1.5 T: 957 ± 22 vs.
941 ± 58; 3 T 1043 ± 23 vs. 1072 ± 63, p < 0.05) [16].
Comparisons of T1 values between the core lab and
investigator sites
There was close agreement between T1 values obtained
in core-lab and locally for all sites for native septal and
SAX T1 measurements (a mixed sample of 1.5 T and 3 T
cases from all sites, n = 9, p = 0.57 and p = 0.42; between
sites comparisons, repeated measures ANOVA) (Figure 4).
Post-contrast values showed lower concordance for both
septal and SAX T1 measurements (p = 0.104 and p = 0.08).
Comparisons of T1 indices for age, gender, contrast dose
and investigator sites
Age groups were determined by separating the entire
study population into quartiles (group 1: ≤30 years (1.5 T,
n = 27, 3 T = 26), group 2: 31 and 42 years (1.5 T, n = 28,
3 T = 27); group 3: 42 and 53 years (1.5 T, n = 27, 3 T = 24),
group 4: ≥ 53 years (1.5 T, n = 28; 3 T = 28) (Figure 5).
T1-values were similar across the age groups for any field
strength (Table 2). Comparisons of mean values between
the participating sites revealed no significant difference for
native T1 (F = 1.9, p = 0.86), λ (F = 0.4, p = 0.89) and ECV
(F = 0.3, p = 0.91). Mean time from administration to post-
contrast T1 mapping acquisition was 18 ± 4.9 min, with no
significant departures between the sites (F = 2.9, p = 0.61).
A sub-analysis for GBCA dose (Gadovist® 0.1 mmol/kg vs.
0.15 mmol/kg vs. 0.2 mmol/kg) revealed a significant differ-
ence for λ and ECV (Table 3) between the protocols.
Analysis of relationships
There was a trend of a positive association between native
T1 and age at 1.5 T (r = 0.21, p < 0.1 for all), which was
stronger in the male cohort (r = 0.23, p = 0.04) (Figure 6).
There were no such associations noted on 3 T. Comparisons
of native T1, λ and ECV by gender revealed no significant
differences at any field strength (p > 0.05 for all). Native
T1 was mildly associated with LV-EDV, LV-ESV and
LV mass at both field strengths (native T1: 1.5 T: r = 0.21,
p = 0.04; r = −0.24, p = 0.02; r = −0.23, p = 0.03; 3 T: r = 0.13,
p = 0.14; r = −0.21, p = 0.05, r = −0.19, p = 0.07). Results of
inter and intraobserver reproducibility and agreement are
provided in Additional file 1 (Figure 7).
Discussion
We demonstrate that myocardial T1 values obtained
in an investigator-led, single vendor, multicenter study
based on similar imaging infrastructure and unified
Figure 2 Concordance of T1 values and routine CMR measures between healthy volunteers (n = 102) and a subgroup of patients with
low pretest likelihood of cardiovascular disease (n = 113).
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core lab as well as the participating sites by standardized
image acquisition and post-processing approach. We
provide reference values for native T1 and hybrid mea-
sures for 1.5 and 3 T magnetic field strengths in healthy
human myocardium. The present study provides a proof
of transferability of a T1 mapping methodology beyond
a single (and expert) center and suggests a pathway towards
a wider use of T1 mapping.
A substantial body of evidence suggests that T1 mapping
is sufficiently accurate, reproducible and robust to enter
into clinical translational pathway; T1-values were found
abnormal in a variety of cardiomyopathies and permit dis-
crimination between normal and abnormal myocardium.
Thus far, a couple of studies reported on the associations
with outcomes, albeit short-term, in a selected patient
population and single centre set-ups [22,23]. Difficulties
for immediate clinical translation also relate to the ongoing
technical evolution of T1 mapping sequences, scarcity of
multicenter and prospective controlled studies as well as
outcome evidence in subgroups and in large populations
[11,24]. This is the first study to provide reference values
for myocardium healthy humans, including native T1 and
ECV based on a unified T1 mapping methodology at both
field strengths, in a multicenter setting. The average T1
values obtained at 1.5 T field strength are closest to the
segmental values obtained by Messroghli et al. [13,20,25]
using MOLLI in its original form, 3(3)3(3)5, which wasalso used for the current data acquisition. Advances in MRI
scanning equipment with improved coils and shimming,
combined with a rigorous postprocessing approach with
motion correction, as well as considerably greater sample
size, may explain the lower spread of native T1 values
observed in the present study. Subsequent generations of
MOLLI sequence, which introduced several parameter
modifications, most noticeably a lower flip angle of 35°
(compared to 50° in the original sequence), showed similar
average myocardial native T1 values in healthy volunteers
(Messroghli: 939 ± 24 msec; Piechnik, 976 ± 46 msec)
[26,27], and were also implemented across other vendor
platforms. A series of publications from a single centre
(National Institutes of Health, NIH) revealed either similar
values at 1.5 T (Gai et al. 986 ± 168 msec, FA = 50° [28]; Liu
et al.: native T1: 977 ± 42 msec, FA 35° [12]) or higher native
T1 values (Nacif et al. native T1: 1034 ± 56 msec, FA 35°)
[29], with considerably greater scatter. T1 relaxation times
increase with higher field strength, which is also reflected in
our findings: myocardial native T1 values at 3 T are approxi-
mately 100 msec longer in comparison to 1.5 T. This obser-
vation is concordant with previous studies, including by
Piechnick et al. (average SAX 1169 ± 45 msec) [27], and sev-
eral publications from the NIH (Kawel et al. 1286 ± 59 msec
[30]; Lee et al. (1315 ± 39 msec) [31], and more recently,
Von Knobelsdorff-Brenkenhoff et al. (1159 ± ~73 msec)
[32]. The magnitude of native T1 values at 3 T observed in
the present multicenter study concord with the values in
Figure 3 Segmental variations of T1 values in midventricular short axis slice (SAX, segments 7–12) at 1.5 T and 3 T field strengths.
Bull’s eye with annotated segments in midventricular SAX slice.
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previously [14-16], supporting the unchanging source of
results based on a uniform imaging platform. We also
provide further insights into the reference ranges for λ
and ECV based on a MOLLI sequence at both field
strengths based on the bolus technique [19,22,30]. Our
findings concord with previous reports concerning the
average and spread of ECV values in healthy subjects
(at 1.5 T: Liu et al. 0.27 ± 0.03 (calculated as an average of
values for men: 0.26 ± 0.03 and women: 0.28 ± 0.03) [12],
Wong et al. ~0.24 ± 0.02 [22]; at 3 T: Kawel et al. ~0.29 ±
0.03 (estimated from the Figure 2 at ~20 min time-point)
[30], Lee et al. 0.27 ± 0.10 [31]), and the independency of
the calculated parameters from the field strengths.
Sequence parameters, vendors’ specific set-up and stan-
dardized acquisition in part explain the observed diversity
in T1 values in the above studies. A standardized approach
to postprocessing is an additional important consideration
for reproducibility and spread of T1 measurements, allow-
ing robust discrimination between health and disease. We
and others have previously shown that there are signifi-
cant regional variations of native T1-values in SAX slicesof normal subjects [16,27,33-35], with differences between
the septal and lateral segments ranging between 60 to
150 msec. We have previously shown that native T1
measurement in the septum provide the most robust
post-processing approach with an excellent intra-observer
and inter-observer reproducibility irrespective of the field
strength [14-16]. We now show that this post-processing
approach is robust also in a multicenter setting, providing
meaningful values on the expected reference ranges in
healthy myocardium. Regional variation in segmental
values may also account for a higher spread of values
in some of the above studies, because T1 measurements in
average SAX approach integrate native T1 values observed
in all myocardial segments. It is unlikely that these regional
differences represent a true difference in tissue composition.
We found no relationship between T1 values and age.
Several previous publications showed decreasing native
T1 values [36] or increasing ECV values with age [12,22].
Whereas decreasing trend with age is difficult to explain,
the latter studies used a cross-sectional study design and
investigated subclinical or overt disease, respectively. We
have shown previously that T1 values increase with age in
Figure 4 Concordance between measurements obtained at core lab and at participating sites for native and postcontrast septal and
short axis slice (SAX) measurements in a random sample of 9 cases from all sites (KCL – King’s College London, Leeds – University of
Leeds, DHZB – Deutsches Herzzentrum Berlin (German Heart Institute Berlin), Sydney – Vincent University, Sydney Australia.
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previous results in healthy cohorts indicates that charac-
terisation of healthy aging of the myocardium is challen-
ging and complicating simple comparisons of age-related
changes in T1 values. Previous studies also showed associ-
ations with gender, whereby age-dependency was stronger
in men, and older females displaying higher native T1 or
hybrid values [12,36]. We found no gender differences in
T1 values and a weak association for hybrid indices with
males at 1.5 T; however, we could not reproduce such
trend at 3 T. Of note, in a selected subgroup of subjects
with very low cardiovascular risk, Liu et al. showed noECV differences between women and men [12], analogous
to our findings. It is possible that age and gender differ-
ences in T1 values may relate to subclinical and clinical
disease in cross-sectional studies, but may not be a
profound feature in healthy aging. Lastly, whereas all
sites used a single type of GBCA, gadobutrol, we reveal
that non-uniformity of contrast agent doses leads to
appreciable differences in hybrid indices at both field
strengths. These findings were not expected, as it is
generally considered that λ and ECV account for most of
these sources of variation, which otherwise complicate
cross-sites comparisons [9,28].
Figure 5 Distribution of native T1 values for age and gender. Age groups were determined by separating the entire study population into
quartiles (group 1: ≤30 years (1.5 T, n = 27, 3 T = 26), group 2: 31 and 42 years (1.5 T, n = 28, 3 T = 27); group 3: 42 and 53 years (1.5 T, n = 27, 3 T = 24),
group 4: ≥ 53 years (1.5 T, n = 28; 3 T = 28).
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A few limitations apply to this study. It is recognized
that the MOLLI variant used in our study affords a
greater precision in terms of tissue characterisation
(i.e. discrimination between health and disease) compared
to the measurements derived from other MOLLI scheme
variants (which are more accurate in terms of T1 value es-
timation) [10,11], therefore, our ECV calculation is likelyTable 2 T1 values per age, gender and contrast dose
1.5 T 3 T
(n = 110) (n = 105)
Age categories
Native T1 (msec)
Group 1 952 ± 22 1053 ± 26
Group 2 953 ± 25 1057 ± 24
Group 3 957 ± 25 1058 ± 25
Group 4 965 ± 18 1052 ± 24
Sig. (p-value) F = 1.30, p = 0.28 F = 1.16, p = 0.21
Gender Native T1 (msec)
Males 955 ± 23 1053 ± 25
Females 957 ± 23 1054 ± 25
Sig. (p-value) 0.44 0.87
Age groups were determined per quartiles: group 1: ≤30 years (1.5 T, n = 27, 3 T = 2
(1.5 T, n = 27, 3 T = 24), group 4: ≥ 53 years (1.5 T, n = 28; 3 T = 28). Student t-test orto be more precise. Ongoing advances and optimization
of MOLLI schemes and pulse sequence parameters have
shown that estimation of true T1 values can be obtained
with greater accuracy [10,11]. However whilst improved
accuracy is attainable, high precision of T1 estimates
supporting ability to discriminate between health and
disease is fundamental, supporting diagnostic and prog-
nostic role of a biomarker in clinical use. Both, precision1.5 T 3 T Sig.
(n = 92) (n = 87) (p-value)
ECV
0.24 ± 0.03 0.24 ± 0.02
0.25 ± 0.04 0.25 ± 0.03
0.24 ± 0.03 0.24 ± 0.04
0.23 ± 0.04 0.23 ± 0.03
F = 1.09, p = 0.46 F = 1.11, p = 0.36
ECV
0.23 ± 0.04 0.24 ± 0.05
0.25 ± 0.03 0.25 ± 0.05
0.36 0.78
6), group 2: 31 and 42 years (1.5 T, n = 28, 3 T = 27); group 3: 42 and 53 years
one-way ANOVA, P < 0.05 is considered significant.
Table 3 Comparisons of hybrid measures for different doses of gadolinium contrast agent as per local protocol
(Gadovist® 0.1 mmol/kg vs. 0.15 mmol/kg vs. 0.2 mmol/kg)
1.5 T 3 T 1.5 T 3 T Sig.
(n = 92) (n = 87) (n = 92) (n = 87) (p-value)
Gadovist® dose λ ECV
0.1 mmol/kg (n = 9/0) 0.53 ± 0.13 / 0.31 ± 0.08 /
0.15 mmol/kg (n = 17/14) 0.46 ± 0.06 0.49 ± 0.07 0.27 ± 0.04 0.30 ± 0.04 0.75
0.2 mmol/kg (n = 73/66) 0.40 ± 0.05 0.43 ± 0.07 0.24 ± 0.04 0.26 ± 0.05 0.05
Sig. (p-value) F = 9.6, p < 0.01 p < 0.05 F = 5.6, p = 0.06 P < 0.01
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for the approach chosen in the current study [14-16]. It
may be argued that optimized FA (e.g. 35°) may be superior
to our choice of 50° due to a higher SNR and less sus-
ceptibility to off-resonance effects [25,37]. However, a
higher FA also leads to stronger magnetisation transfer
effects, which differ between normal and abnormal myo-
cardium, adding to the discriminatory ability of the chosen
method [38]. Asymptomatic healthy subjects represent an
ideal target population for derivation of normal ranges.
In selecting healthy volunteers in our study, we strived
to also account for exclusion of subclinical disease by a
further inclusion criterion of normal findings on routine
CMR [17,39]. These same rigorous inclusion criteria were
applied to the subgroup of normotensive low risk patients,
primarily intended to compensate for the lower number
of contrast studies in healthy volunteers. Because groupsFigure 6 Relationship between native T1 and age separately for fieldwere similar for clinical characteristics and routine CMR
findings (and subsequently T1 values), we believe that
bias introduced by their inclusion in age-gender related
comparisons is negligible. Hematocrit, which is used in
ECV calculation has only been available in a minority of
subjects and has not been sampled at the time of CMR
studies [9]. Thus, normal ranges for hybrid measures
may bear inaccuracies. In the present study we controlled
for, reported on or assessed many of the influences, which
complicate T1 values comparisons, including CMR
platform, technique, pulse sequence parameter selections,
field strength, type of GBCA and post-processing of T1
measurement. While a single vendor platform might
potentially be perceived as a limitation to a wider transfer-
ability of our results, the multicenter nature of our data
overcomes several limitations by delivering evidence, which
is fundamental and immediately useful to the centers usingstrengths.
Figure 7 Interobserver and intraobserver reproducibility of native T1 values.
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http://jcmr-online.com/content/16/1/69same hardware set-up. This adds to the future potential
of providing T1 mapping as a commercial clinical appli-
cation as the evidence continues to emerge. Evidence
for robustness of clinical applications also enhances the
chances for multivendor agreements, providing the clar-
ity on a common minimum standard for clinical appli-
cation of a T1 mapping sequence.
Conclusions
In this study we provide a proof of transferability for
a T1 mapping methodology beyond a single (expert)
center, suggesting a pathway for an extended utility of
T1 mapping. Based on a unifying and standardizedimaging and postprocessing approach we provide refer-
ence T1 values in healthy subjects at both field strengths.
Additional file
Additional file 1: Summary of the inter and intra-observer
reproducibility sub-study of T1 measurements.
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